Recent Updates
Recently added Catalysts
AZN Positive Sentiment

AstraZeneca results: 9M and Q3 2026

Friday, October 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AstraZeneca reported total revenue of 46,881 million for the first nine months of 2026, an 8 percent increase. Product sales grew by 7 percent during this period. Core EPS reached 8.00, up 14 percent. Reported EPS was 5.62, reflecting 10 percent growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Product sales increased by 7% in 9M 2026.
  • Alliance revenue rose by 33% in Q3 2026.
  • Reported EPS grew by 10% for 9M 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
Elecoglipron
Phase 3 · Type 2 Diabetes Mellitus

Full Press Release Details

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary   9M 2026 % Change Q3 2026 % Change   $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7 7 Reported EPS ($) 5.62 10 11 2.02 23 26 Core2 EPS ($) 8.00 14 14 2.79 17 19 Key performance elements for 9M 2026 (Growth numbers at constant exchange rates

Frequently Asked Questions

What was AstraZeneca's total revenue for 9M 2026?

Total revenue reached 46,881 million, up 8 percent.

How much did product sales grow in Q3 2026?

Product sales grew by 5 percent in Q3 2026.

What was the reported EPS for AstraZeneca in 9M 2026?

Reported EPS was 5.62, reflecting 10 percent growth.

What was the alliance revenue change in Q3 2026?

Alliance revenue increased by 36 percent in Q3 2026.

ShareAdd on Google
Tags: AZN AstraZeneca Q3 2026 financial results revenue growth EPS
Last updated: Oct 30, 2026

Biotech snapshot

Lead asset
ElecoglipronPhase 3
Type 2 Diabetes Mellitus →

Catalyst track record

+12%
best trade around AZN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for AZN.

See every catalyst's timing & PoA →